Clinical Outcome of Severe, Recalcitrant or Steroid Contraindicated Pemphigus Treated with Intravenous Immunoglobulin : A Case Series

Authors

  • Oraya Kwangsukstid, M.D.

Keywords:

Intravenous immunoglobulin, IVIG, Severe pemphigus, Rrecalcitrant pemphigus, Steroid contraindicated, Treatment

Abstract

Background : Intravenous immunoglobulin (IVIG) has been used as an adjuvant treatment in severe, recalcitrant or steroid contraindicated pemphigus patients. Rapidly disease controlled without immunosuppression was a significant advantage different from other treatment modalities.

Objectives : This study aimed to evaluate the clinical response, and side effects of IVIG treatment in severe, recalcitrant, or steroid contraindicated pemphigus patients.

Methods : A retrospective review was conducted at the Institute of dermatology over seven years. Pemphigus patients who received at least six cycles of IVIG as adjuvant treatment were recorded demographic data, treatment before IVIG, indication for IVIG, dose, type, and the number of IVIG cycles. Clinical remission was evaluated at one month after the 6th cycle of IVIG. A dose of prednisolone before and after IVIG treatment was recorded. An adverse event was monitored.

Results : Eleven pemphigus vulgaris patients, three with active extensive involvements, six with treatment recalcitrant and two with side effects or contraindication to systemic steroids and immunosuppressive agents were reviewed. Ten of eleven patients (90.9%) showed a response to six cycles of IVIG, five (45.5%) having complete remission. All five patients remained in remission during the 4-28 months follow up period. Mean prednisolone dose reduction was 57.3% in IVIG response patients. The therapy was well tolerated; however, congestive heart failure occurred in one patient with an underlying left ventricular hypertrophy. One patient developed cutaneous side effect which response to topical steroid. One extensive pemphigus patient did not respond to IVIG and died of sepsis and multi-organ failure.

Conclusions : Adjuvant six cycles of IVIG treatment in severe, recalcitrant, or steroid contraindicated pemphigus patients increased disease control, induced remission, and demonstrated steroid-sparing effect. The results encourage the use of IVIG due to the safety and effectiveness.

Downloads

Download data is not yet available.

References

Saha M, Bhogal B, Black MM, Cooper D, Vaughan RW, Groves RW. Prognostic factors in pemphigus vulgaris and pemphigus foliaceus. Br J Dermatol 2014;170:116-22.

Huang YH, Kuo CF, Chen YH, Yang YW. Incidence, mortality,and causes of death of patients with pemphigus in Taiwan:a nationwide population-based study. J Invest Dermatol 2012;132:92-7.

Kridin K, Zelber-Sagi S, Bergman R. Risk factors for lethal outcome in patients with pemphigus: a retrospective cohort study. Eur J Dermatol 2018;28:26-37.

Bystryn JC, Steinman NM. The adjuvant therapy of pemphigus:an update. Arch dermatol 1996;132:203-12.

Martin LK, Werth VP, Villaneuva EV, Murrell DF. A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus. J Am Acad Dermatol 2011;64:903-8.

Atzmony L, Hodak E, Leshem YA, Rosenbaum O, Gdalevich M,Anhalt GJ, et al. The role of adjuvant therapy in pemphigus:a systematic review and meta-analysis. J Am Acad Dermatol 2015;73:264-71.

Tavakolpour S. Current and future treatment options for pemphigus: Is it time to move towards more effective treatments?. Int Immunopharmacol 2017; 53:133-42.

Atzmony L, Hodak E, Gdalevich M, Rosenbaum O, Mimouni D. Treatment of pemphigus vulgaris and pemphigus foliaceus:a systematic review and meta-analysis. Am J Clin Dermatol 2014;15:503-15.

Murrell DF, Pena S, Joly P, Marinovic B, Hashimoto T, Diaz LA, et al. Diagnosis and management of pemphigus:recommendations by an international panel of experts. J Am Acad Dermatol 2020;82:575-85.

Hertl M, Jedlickova H, Karpati S, Marinovic B, Uzun S,Yayli S, et al. Pemphigus. S2 Guideline for diagnosis and treatment–guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol 2015;29:405-14.

Harman KE, Brown D, Exton LS, Groves RW, Hampton PJ,Mohd Mustapa MF, et al. British Association of Dermatologists’guidelines for the management of pemphigus vulgaris. Br J Dermatol 2017;177:1170-201.

Bystryn JC, Rudolph JL. IVIg treatment of pemphigus: how it works and how to use it. J Invest Dermatol 2005;125:1093-8.

Bystryn JC, Jiao D. IVIg selectively and rapidly decreases circulating pathogenic autoantibodies in pemphigus vulgaris. Autoimmunity 2006;39:601-7.

Green MG, Bystryn JC. Effect of Intravenous immunoglobulin therapy on serum levels of IgG1 and IgG4 antidesmoglein 1 and antidesmoglein 3 antibodies in pemphigus vulgaris. Arch Dermatol 2008;144:1621-4.

Lolis M, ToosiS, Czernik A, Bystryn JC. Effect of intravenous immunoglobulin with or without cytotoxic drugs on pemphigus intercellular antibodies. J Am Acad Dermatol 2011;64:484–9.

Aoyama Y. What’s new in i.v. immunoglobulin therapy and pemphigus: high-dose i.v immunoglobulin therapy and its mode of action for treatment of pemphigus. J Dermatol 2010;37:239-45.

Czernik A, Beutner EH, Bystryn JC. Intravenous immunoglobulin selectively decreases circulating autoantibodies in pemphigus. J Am Acad Dermatol 2008;58:796-801.

Ahmed AR. Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment. J Am Acad Dermatol 2001;45:679-90.

Bystryn JC, Jiao D, Natow S. Treatment of pemphigus with intravenous immunoglobulin. J Am Acad Dermatol 2002;47:358-63.

Sami N, Qureshi A, Ruocco E, Ahmed AR. Corticosteroidsparing effect of intravenous immunoglobulin therapy in patients with pemphigus vulgaris. Arch Dermatol 2002;138:1158-62.

Mittmann N, Chan B, Knowles S, Mydlarski PR, Cosentino L,Shear N. Effect of intravenous immunoglobulin on prednisone dose in patients with pemphigus vulgaris. J Cutan Med Surg 2006;10:222–7.

Baum S, Scope A, Barzilai A, Azizi E, Trau H. The role of IVIg treatment in severe pemphigus vulgaris. J Eur Acad Dermatol Venereol 2006;20:548–52.

Mignogna MD, Leuci S, Fedele S, Ruoppo E, Adamo D, Russo G, et al. Adjuvant high-dose intravenous immunoglobulin therapy can be easily and safely introduced as an alternative treatment in patients with severe pemphigus vulgaris: a retrospective preliminary study. Am J Clin Dermatol 2008;9:323-31.

Amagai M, Ikeda S, Shimizu H, Iizuka H, Hanada K, Aiba S, et al. A randomized double-blind trial of intravenous immunoglobulin for pemphigus. J Am Acad Dermatol 2009;60:595-603.

Svecova D. IVIG therapy in pemphigus vulgaris has corticosteroid-sparing and immunomodulatory effects. Australas J Dermatol 2016;57:141-4.

Ahmed AR, Dahl MV. Consensus statement on the Use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases. Arch Dermatol 2003;139:1051-9.

Seidling V, Hoffmann JHO, Enk AH, Eva NH. Analysis of high-dose intravenous immunoglobulin therapy in 16 patients with refractory autoimmune blistering skin disease: high efficacy and no serious adverse events. Acta Derm-Venereol 2013;93:346-9.

Gürcan HM, Ahmed AR. Frequency of adverse events associated with intravenous immunoglobulin therapy in patients with pemphigus or pemphigoid. Ann Pharmacother 2007;41:1604-10.

The sub-committee for develop national list of essential medicine. Human normal intravenous immunoglobulin (IVIG) in severe and recalcitrant pemphigus vulgaris. In: Thai National Formulary 2010: special access medicines of national list of essential medicines. 1st ed. Bangkok: The Agricultural Cooperative Federation of Thailand; 2010. p. 74-6.

Murrell DF, Dick S, Ahmed AR, Amagai M, Borradori L, Bystryn JC, et al. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J Am Acad Dermatol 2008;58:1043–6.

Ahmed AR, Spigelman Z, Cavacini LA, Posner MR. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med 2006;355:1772-9.

Ahmed AR, Nguyen T, Kaveri S, Spigelman ZS. First line treatment of pemphigus vulgaris with a novel protocol in patients with contraindications to systemic corticosteroids and immunosuppressive agents: preliminary retrospective study with a seven-year follow-up. Int Immunopharmacol 2016;34:25-31.

Grando SA. Retrospective analysis of a single-center clinical experience toward development of curative treatment of 123 pemphigus patients with a long-term follow-up: efficacy and safety of the multidrug protocol combining intravenous immunoglobulin with the cytotoxic immunosuppressor and mitochondrion-protecting drugs. Int J Dermatol 2019;58:114–25.

Guo Y, Tian X, Wang X, Xiao Z. Adverse effects of immunoglobulin therapy. Front Immunol 2018;9:1-13.

Published

10-03-2021

How to Cite

1.
อรยา กว้างสุขสถิตย์ พ.บ. Clinical Outcome of Severe, Recalcitrant or Steroid Contraindicated Pemphigus Treated with Intravenous Immunoglobulin : A Case Series . j dept med ser [Internet]. 2021 Mar. 10 [cited 2022 Aug. 14];45(4):215-2. Available from: https://he02.tci-thaijo.org/index.php/JDMS/article/view/249817

Issue

Section

Original Article